Just in time for the most recent outbreak of Ebola in Africa, which potentially has already spread into North America via Canada, the National Institute for Health is licensing a Rabies based Ebola vaccine produced by Exxell Bio.
"trivalent filovirus vaccine based on killed rabies virus virions for use in humans to confer protection from all medically relevant filoviruses and RABV. Two additional vectors containing EBOV Sudan GP or MARV GP are planned to be constructed in addition to the previously developed EBOV Zaire GP containing vaccine. Live attenuated vaccines have been developed for use in at risk nonhuman primate populations in Africa and inactivated vaccines have been developed for use in humans."
Basically, what they have done here is taken the Rabies virus and altered its exterior coating to contain Ebola proteins. So if all works as planned, the person vaccinated is protected from Rabies and Ebola. Or course such things often have unintended consequences, we'll make a wager that giving live attenuated Ebola modified Rabies vaccines to wild non-human primates in Africa may result in some unusual and deadly selection pressures.
These efforts seem to tie in with recent government contracts to increase capacities at CDC Quarantine Stations located throughout the country. In similar regard, the government has also laid out its plans to reimburse people from injuries caused by governmental Pandemic actions. All these actions are tied in with a large Federal effort to mitigate the impact of a Zero Day Pandemic Exploit. (see sources below)
Prospective Grant of Exclusive License: Multivalent Vaccines for Rabies Virus and Ebola and Marburg (Filoviruses)
edited to add a research study on this type of vaccine-